| A. | AMRI      Services: |
|----|---------------------|

|   | 1. | SPRI may engage AMRI to perform chemistry      services, which may include consulting, chemical synthesis, chemical      process research, analytical methods development, validation or release      testing, and other related services      (collectively, the “Services”) in connection with one or more projects      (each a “Project” and collectively, the “Projects”) during the Term (as      hereinafter defined) as mutually agreed by the Parties from time to time      pursuant to one or more written Research Project Appendices in the form of      Appendix 1 attached hereto (each a “Research Project Appendix” and      collectively, the “Research Project Appendices”).  AMRI shall      not commence work on any Project or provide any Services until the parties      enter into a Research Project Appendix, which will set forth (i) the      Services to be performed by AMRI (including deliverables to be provided to      SPRI in connection therewith), (ii) the timing for the Project (including      relevant deadlines and delivery dates for deliverables), (iii) the cost      and payment schedule with respect to such Services, (iv) any individuals      designated to have management responsibility for the Project or otherwise      required to perform the Services, and (v) to the extent necessary and      appropriate, additional provisions applicable to the Services to be      provided pursuant to the Research Project Appendix which shall not be      inconsistent with the terms of this Agreement and which are not otherwise      set forth in this Agreement.  Any terms or conditions included      in a Research Project Appendix other than those described in this Section      A.1. shall be deemed to conflict with this Agreement and shall have no      force or effect.  References in this Agreement to this      “Agreement” shall be deemed to include any Research Project Appendix      entered into pursuant hereto, subject to the preceding      sentence.  The parties expressly agree that the terms hereof      cannot be altered by course ofdealings. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 2. | Anything to the contrary contained in this      Agreement notwithstanding, AMRI acknowledges and agrees that there is no      minimum number of Projects for which SPRI is obligated to engage the      services of AMRI and this Agreement shall not be construed as limiting in      any way SPRI’s right to contract for any services with any other      party. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | In no event shall this Agreement be construed as      obligating SPRI to pay any amounts for Services performed under this      Agreement unless (i) SPRI actually engages AMRI to perform Services      pursuant to this Agreement, (ii) such engagement is evidenced by a      Research Project Appendix in the form of Appendix 1 entered into pursuant      to this Agreement by the parties prior to the commencement of any such      engagement, and (iii) AMRI complies with the procedures set forth in      Section F.2. herein.  AMRI acknowledges and agrees that verbal      authorization or instructions from SPRI or any of its affiliates to      commence work or Services shall not be sufficient and shall have no force      or effect and that any work or Services performed by AMRI prior to      execution by the parties of a Research Project Appendix for the engagement      shall be at the sole risk and expense of AMRI.  The parties      expressly agree that this provision cannot be altered by course of      dealings. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | SPRI will define and the parties shall      mutually agree upon the parameter of the Projects and define the time      frame in which the Services are to be      provided as requested.  Such Projects shall include, but not be      limited to, the following: |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a) | Product Development      Assistance:  AMRI shall be available to SPRI to advise on      design and synthesis of organic compounds, to perform process chemistry      and analytical services, and/or to complete the manufacture of organic      compounds, subject to mutually acceptable Research Project Appendices      governing the requested projects.  Such Research Project      Appendices will specify the work to be undertaken, the conditions and      timing under which work is to be completed, and the amount of AMRI’s      compensation. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | Technical      Assistance:  AMRI shall be available to SPRI to perform      synthetic chemical research, medicinal chemistry, process development, and      process optimization studies.  The chemistry and scope of work      is to be defined under mutual agreement between AMRI and    SPRI. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c) | Technical      Consultations:  AMRI shall be available to SPRI at such      times as are requested by SPRI for technical consultations with SPRI’s      Research and Development personnel via telephone.  AMRI shall be      available for consultation at mutually agreed upon sites, provided that      the extent of this activity will be set by mutual agreement of SPRI and      AMRI.  SPRI shall reimburse AMRI for [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/] |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| B. | Specific Duties of      AMRI: |
|----|-------------------------------|

|   | 1. | In      assuming responsibility for undertaking this Agreement, AMRI      will: |
|--------|----|---------------------------------------------------------------------------------|

|   | a) | Perform      chemistry consulting, computational services, synthetic chemical research,      medicinal chemistry, process development and process optimization studies,      and manufacturing of specialty chemicals for any Projects entered      into. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | Provide      technical consultation, technical assistance and product development      assistance, as defined, for any Projects entered  into. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c) | Develop      or utilize existing analytical methods which will allow determination of      the identity and quantification of the purity of any compounds      delivered. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | d) | Provide      Services and/or compounds as      expeditiously as possible. |
|--------|----|---------------------------------------------------------------------------|

|   | e) | Provide      to SPRI Certificates of Analysis to include, as appropriate, elemental      analysis, optical rotation, HPLC analysis, NMR spectra, and an IR spectrum      on any compounds provided. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | f) | Perform      experiments using standard and accepted good laboratory practices and      current Good Manufacturing Practices, techniques, and record keeping      procedures, as appropriate to eachproject. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | g) | Interact      with SPRI’s scientists as is deemed appropriate in the conduct of a fully      integrated drug discovery project teameffort. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------|

|   | h) | Interact      with and communicate with SPRI, to its satisfaction, and upon all      requests, regarding any Projects. |
|--------|----|------------------------------------------------------------------------------------------------------------------------|

|   | i) | Provide      written research reports to SPRI describing the results and including full      experimental procedures, due upon mutually agreed upon interim dates and      upon the completion of individualProjects. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | j) | Retain      experimental records and laboratory notebooks containing experimental      descriptions and data generated from this work for a period of seven (7)      years.  After this time and on request by SPRI, AMRI shall      provide to SPRI all experimental records and laboratory notebooks, or      copies thereof, containing information from the Projects for retention in      SPRI’s archives. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| C. | SPRI’s      Obligations:  SPRI will: |
|----|------------------------------------------------------|

|   | 1. | Provide      research samples, chromatographic information, and appropriate structural      characterization spectra of relevant compounds to AMRI, as agreed to by      SPRI. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | Provide      intermediates to AMRI where (and if) AMRI and SPRI mutually agree to be      appropriate for project conduct andcompletion. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | Agree      to pay AMRI for the Services to be performed by AMRI as set forth in      Section F.2. herein and agreed upon in the applicable Research Project      Appendix. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| D. | Confidentiality: |
|----|------------------|

|   | 1. | With      respect to any and all information indicated as being or which reasonably      appears to be or is marked to be confidential, including, but not limited      to, chemical synthesis or process data, proprietary chemicals, preclinical      and clinical data and program results, or any other information or data      acquired or generated by AMRI as a result of this Agreement or from      performance of the Services to be rendered hereunder (“SPRI Confidential      Information”), AMRI agrees that it will not, and will not permit any of      its employees, consultants, or representatives to, use said information      other than for the purposes of this Agreement, it will not, and will not      permit any of its employees, consultants, or representatives to, disclose      any of said information to a third party except as is required pursuant to      the purposes of this Agreement, and it will not, and will not permit any      of its employees, consultants, or representatives to, publish or submit      for publication said information without SPRI’s prior      approval.  AMRI shall only disclose SPRI Confidential      Information to AMRI’s employees, consultants or representatives who have      entered into written confidentiality and non-use agreements with AMRI      having terms substantially similar to those set forth in this      Agreement. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | AMRI      agrees to utilize all reasonable efforts to create confidentiality      firewalls between different groups of its employees working on different      Projects under this Agreement so that SPRI Confidential Information from      one Project is not disclosed to AMRI employees working on a different      Project. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | AMRI’s      obligation with regard to confidential information, which is a Trade      Secret (as defined herein) shall continue at all times from and after the      date of this Agreement, and with regard to confidential information which      is not a Trade Secret, shall continue for a period of five (5) years from      the date of termination of this Agreement.  For purposes of      this Agreement, the term “Trade Secrets” shall      mean:  information including, but not limited to, technical or      nontechnical data, a formula pattern, compilation, program, device,      method, technique, drawing, process, financial data, or list of actual or      potential customers or supplierswhich: |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | Derives      economic value, actual or potential, from not being generally known to      other persons who can obtain economic value from its disclosure or use;      and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (ii) | Is      the subject of efforts that are reasonable under the circumstances to      maintain its secrecy orconfidentiality. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------|

|   | 4. | The      foregoing obligations shall not apply to information which is or lawfully      becomes generally available to the public through no fault of AMRI, which      is lawfully acquired from third parties who have a right to disclose such      information, or which by mutual agreement is released from a confidential      status. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| E. | Term and      Termination: |
|----|----------------------------|

|   | 1. | This      Agreement shall commence on the date first set forth above and shall      terminate after three (3) years, unless earlier terminated by either party      hereto (the “Term”).  The Term of this Agreement may be extended      by mutual written agreement of theparties. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | The      representations and warranties contained in this Agreement (including the      recitals hereto), as well as those rights and/or obligations contained in      the terms of this Agreement which by their intent or meaning have validity      beyond the term hereof, including without limitation Sections D, I, and      K.3. hereof, shall survive the expiration or termination of this      Agreement. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | This      Agreement may be terminated prior to the expiration of the term only under      the following Conditions: |
|--------|----|---------------------------------------------------------------------------------------------------------------------|

|   | a) | By      either party, if the other party materially breaches any of the covenants      and agreements under this Agreement, upon thirty (30) days written notice      to the other party. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | By      SPRI, if AMRI is substantially unable to perform assigned duties hereunder      whether due to sickness, disability or incapacity, or any other reason,      upon thirty (30) days written notice toAMRI. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c) | By      AMRI, if SPRI fails to pay fees and/or fails to reimburse AMRI for      reimbursable expenses as provided in Section F.2. upon thirty (30) days      written notice to SPRI. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | d) | [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] may terminate this      Agreement or any Project [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] upon      written notice to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] under the      [/*[CONFIDENTIAL TREATMENTREQUESTED]*/]: |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (i) | if      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] desires to terminate the      Agreement or any Project [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] and      wind-down any Projects, [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] shall      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] the then current number of      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] until the total number of      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] have been [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/]; or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | if      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] desires to terminate the      Agreement or any Project [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], then      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] shall [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/] the      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] charges [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] under the [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]      as described [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] using the      [/*[CONFIDENTIAL TREATMENTREQUESTED]*/]. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | If      any Research Project Appendix entered into prior to the end of the Term      shall have an expiration date after the last day of the Term, then      nothwithstanding the end of the Term set forth in this Section E, this      Agreement shall remain in full force and effect until the expiration of      such Research Project Appendix and references herein to “Term” shall refer      to the period ending with the expiration date of such Research Project      Appendix, but only with respect to such Research Project Appendix and the      Services described therein. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| F. | Communications and      Payments: |
|----|-----------------------------------|

|   | 1. | Communications:  All      communications associated with this Agreement shall be by first class mail      or courier, addressed to the respective parties as  follows: |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| To      AMRI:        | Chief      Financial Officer                            |
|----------------------|---------------------------------------------------------|
|                 | Albany      Molecular Research, Inc                     |
|                 | 21      Corporate Circle                                |
|                 | Albany,      New York 12203-5154                        |
|                 |                                                    |
| With      a copy to: | Director,      Contracts, Licensing & Legal Affairs |
|                 | Albany      Molecular Research, Inc                     |
|                 | 21      Corporate Circle                                |
|                 | Albany,      New York 12203-5154                        |
|                 |                                                    |
| To      SPRI:        | Vice      President, Chemistry                          |
|                 | Schering-Plough      Research Institute                 |
|                 | 2015      Galloping Hill Road                           |
|                 | Kenilworth,      NewJersey  07033             |

----

| With      a copy to: | Director,      Discovery Collaborations |
|----------------------|-----------------------------------------|
|                 | Schering-Plough      Research Institute |
|                 | 2015      Galloping Hill Road           |
|                 | Kenilworth,      NJ  07033    |

|   | 2. | Payments:  In      consideration of the Services that are performed by AMRI under this      Agreement, SPRI will pay AMRI at the following [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/] for work conducted pursuant to agreed upon [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/]: |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a) | Fees:  The      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] rate per FTE is outlined in the      table below.  When the total number of FTEs employed under this      Agreement triggers [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] in the      applicable FTE rate below, then that [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/] shall [/*[CONFIDENTIAL TREATMENT    REQUESTED]*/]. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Number of FTEs                      |   | [/*[CONFIDENTIALTREATMENTREQUESTED]*/]RatePer FTE |   | Estimated [/*[CONFIDENTIALTREATMENT REQUESTED]*/]Expenses per [/*[CONFIDENTIALTREATMENT REQUESTED]*/]per FTE |
|-----------------------------------------------|--------|--------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------|
| [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] |   | $[/*[CONFIDENTIAL      TREATMENT REQUESTED]*/]         |   | $[/*[CONFIDENTIAL      TREATMENT REQUESTED]*/]                                                                                             |
| [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] |   | $[/*[CONFIDENTIAL      TREATMENT REQUESTED]*/]         |   | $[/*[CONFIDENTIAL      TREATMENT REQUESTED]*/]                                                                                             |
| [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] |   | $[/*[CONFIDENTIAL      TREATMENT REQUESTED]*/]         |   | $[/*[CONFIDENTIAL      TREATMENTREQUESTED]*/]                                                                                              |

----

|   | b) | Reimbursed      Expenses:  SPRI will reimburse AMRI for [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] reasonable and necessary expenses [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] while [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]      pursuant to this Agreement and which are in accordance with SPRI’s      Reimbursement Policy, a copy of which is attached hereto as Appendix 2.  AMRI shall submit      signed requests with each invoice for reimbursement on AMRI’s letterhead      or other identifying stationery (“Expense Reports”), accompanied by a      reasonably detailed list of expenses.  [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] reimbursable expenses shall not [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] an aggregate total of [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/] multiplied by the [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]      working on SPRI projects without prior authorization from SPRI, such      authorization shall not be unreasonably delayed or      withheld.  Reasonable and necessary expenses shall include:      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] used directly in the Projects;      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], etc.); [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] used directly in the Projects; [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] used in the Projects (upon authorization by SPRI      to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]; and, [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] requested by SPRI.  AMRI will not      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], nor [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/] in the normal course of performing  Services. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | [CONFIDENTIAL      TREATMENT REQUESTED BY AMRI –03] |
|--------|-----------------------------------------------------------|

| G. | Assignment: |
|----|-------------|

|   | Neither      party shall have the right to assign this Agreement or any of the rights      or obligations hereunder without the prior written consent of the other      party, except that either party may assign this Agreement to an affiliate      without such prior consent. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| H. | Entire      Agreement: |
|----|------------------------|

|   | 1. | This      Agreement represents the entire agreement of the parties with respect to      the subject matter hereof and supersedes all prior understandings and      agreements with respect thereto. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | No      change or modification of the provisions of this Agreement shall be      effective unless it is in writing and signed by a duly authorized officer      of AMRI and SPRI. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| I. | Project Ownership and      Retention of Records: |
|----|--------------------------------------------------|

|   | 1. | Subject to SPRI satisfying its obligations under      C.3. and F.2., all [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] of      any kind and [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] supplied to AMRI      from SPRI or [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] the Services      performed hereunder shall be the sole and exclusive property of      SPRI.  Any [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], whether      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] or not that may [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] above described or [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/] shall be the sole and exclusive property of SPRI, and AMRI      agrees to assign or cause to be assigned all rights thereto to      SPRI.  AMRI and its employees agree to cooperate with SPRI in      taking all steps which SPRI believes reasonably necessary or desirable to      secure its rights on this property at SPRI’s cost.  In      consideration of the foregoing, SPRI agrees to grant to AMRI      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] to practice any [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] solely generated by AMRI that are specifically      directed to AMRI’s [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], to the extent      such technology has [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]; provided,      however, that such use by AMRI under this [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/] shall not [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] any      program or product [/*[CONFIDENTIAL TREATMENT    REQUESTED]*/]. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | [CONFIDENTIAL      TREATMENT REQUESTED BY AMRI –04] |
|--------|-----------------------------------------------------------|

|   | 2. | During      the term of this Agreement, AMRI shall maintain all written materials and      all other data obtained or generated by AMRI in the course of providing      the Services performed under this Agreement in a secure area reasonably      protected from fire, theft and destruction.  At the expiration      or termination of this Agreement, all written materials and other data and      information obtained or generated by AMRI in the course of providing the      Services will be retained by AMRI in accordance with Section B.1.j or, at      SPRI’s option, be (a) delivered to SPRI or its designee in such form as is      then currently in the possession of AMRI, (b) retained by AMRI for SPRI      for a period of time mutually agreed upon by the parties, or (c) disposed      of, at the direction and written request of SPRI, unless such materials      are otherwise required to be stored or maintained by AMRI as a matter of      law or regulation. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| J. | Safety and      Environmental: |
|----|--------------------------------|

|   | In      carrying out its responsibilities under this Agreement, AMRI agrees to      assure that the Services are conducted in compliance with any applicable      SPRI protocols and/or specifications of which AMRI is reasonably advised      in a timely manner and in compliance with all applicable laws, rules, and      regulations, including, but not limited to, the U.S. Food, Drug and      Cosmetic Act and the regulations promulgated pursuant      thereto.  Also included is compliance with all relevant      environmental regulations in force at the U.S. Federal, State, and Local      levels. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| K. | Miscellaneous: |
|----|----------------|

|   | 1. | AMRI      represents and warrants that it will render the Services hereunder in      accordance with prevailing high professional standards and will make all      reasonable efforts to produce consistently high levels of accuracy and      expertise and to meet timetables set forth under this Agreement for      completion of Services.  AMRI further represents and warrants      that personnel assigned to perform Services under this Agreement shall      have the skills necessary to efficiently perform such Services and shall      produce chemicals, data, and/or reports, as the case may be, in a form and      of a quality suitable to SPRI and that for each group of five (5) AMRI      employees providing Services hereunder, at least two (2) employees shall      have a doctorate degree in the chemistryfield. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | AMRI      will endeavor with all reasonable effort to conform to its obligations      identified herein.  Although no delays or limits beyond AMRI’s reasonable control in      performing any Projects are expected, if such delays or limits are      encountered, AMRI will promptly notify SPRI accordingly and AMRI shall use      all reasonable efforts to eliminate or minimize such delays or      limits.  SPRI agrees to accommodate any reasonable change in      timetables as a result of such delays that AMRI cannot reasonably      eliminate or minimize, provided the Projects have been proceeding to      SPRI’s satisfaction. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | AMRI      will further permit SPRI to audit AMRI’s relevant, non-financial records      during and after the term of this Agreement, but not more than once per      calendar year, solely to permit SPRI to confirm that the Services are or      have been performed in compliance with applicable laws and      regulations. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | AMRI      is an independent company and nothing in this Agreement shall be construed      to create a partnership, joint venture, or employment relationship between      the parties. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5. | AMRI,      on behalf of itself and its employees, agents, subcontractors, and      affiliates agrees not to use the name of SPRI or any of its employees,      agents, affiliates, or subsidiaries, or reference any of their products,      in any publicity, advertising, or other publication without SPRI’s prior      written approval. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6. | If      any provision hereof shall be determined to be invalid or unenforceable,      such determination shall not affect the validity of the other provisions      of this Agreement. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7. | This      Agreement shall be governed in accordance with the laws of the State of      New York. |
|--------|----|--------------------------------------------------------------------------------------------------|

|   | 8. | Waiver      by either party or the failure by either party to claim a breach of any      provision of this Agreement shall not be deemed to constitute a waiver or      estoppel with respect to any subsequent breach of any provision      hereof. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 9. | [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] agrees to assume the liability for injury or      damage caused by [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] provided by      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], provided such [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] is not caused by [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/], intentional activity, or failure to meet required      specifications or breach of any applicable federal, state, or local      law.  [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] to indemnify,      defend, and hold harmless [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] from      any and all liability arising out of such [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/] assessed against it.  [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/] agrees to assume the liability for [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] caused by its [/*[CONFIDENTIAL TREATMENT      REQUESTED]*/], provided such [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] is      not caused by [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], intentional      activity, or failure to meet required specifications or breach of any      applicable federal, state, or local law.  [/*[CONFIDENTIAL      TREATMENT REQUESTED]*/] agrees to indemnify, defend and hold harmless      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] from any and all liability      arising out of said [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], including      but not limited to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] assessed      against it. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Albany      Molecular Research, Inc. |                          | SCHERING      CORPORATION,acting      through its Schering-PloughResearch      Institute division |
|--------------------------------------|-------------------------------|---------------------------------------------------------------------------------------------------|
|                                 |                          |                                                                                              |   |   |
| By:                                  | /s/      Eric W. Smart        |                                                                                              | By: | Cecil      B. Pickett |
|                                 |                          |                                                                                              |   |   |
|                                 |                          |                                                                                              |   | an      authorized representative |
|                                 |                          |                                                                                              |   | of      Schering-Plough Research Institute |
|                                 |                          |                                                                                              |   |   |
| Name:                                | Eric      W. Smart            |                                                                                              | Name: | Cecil      B. Pickett, Ph.D. |
|                                 |                          |                                                                                              |   |   |
| Title:                               | VP,      Business Development |                                                                                              | Title: | President,      SPRI |
|                                 |                          |                                                                                              |   |   |
| Date:                                | January      10, 2006         |                                                                                              | Date: | January      13,2006 |

----

| Purpose: | AMRI      will provide up [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] Full-Time      Equivalent (“FTE”) scientists (to the extent requested by SPRI) for      medicinal chemistry services and synthesis services of compounds as      described below or as may be amended from time to time in subsequent      writings signed by both parties.  A detailed description of the      Project and Services is set forth in Attachment 1, which is incorporated      herein by reference. |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Term: | Appendix      1 is in effect beginning on the Effective Date of the Agreement and      continues in effect until December 31, 2006 or earlier terminated by      either party pursuant to Article E of the Agreement. |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| I. | AMRI      FTE Assignments and Deliverables |
|----|--------------------------------------------|

|   | A. | AMRI      shall prepare compounds for biological screening and other compounds,      scaffolds, and reference compounds as SPRI directs AMRI during the term of      this Research Project Appendix. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | B. | AMRI      shall provide Certificates of Analysis for all compounds, including at      least one proton NMR, mass spectrum, and other characterization as may be      required and mutually agreed to by the parties. AMRI shall conduct      analyses on the compounds pursuant to A) above utilizing appropriate      chromatographic and spectroscopic techniques. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | C. | AMRI      shall prepare written reports on a periodic basis to SPRI detailing the      progress of the research hereunder. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------|

| II.  | SPRI      Resources and Materials |
|-----------|-----------------------------------|

| III.  | Invoicing      and Payment |
|------------|----------------------------|

----

----

| Albany Molecular Research, Inc. |                         | SCHERING      CORPORATION, |
|---------------------------------|------------------------------|----------------------------|
|                            |                         |                       | acting      through its Schering-Plough |
|                            |                         |                       | Research      Institute division |
|                            |                         |                       |   |   |
| By:                             | /s/      Eric W. Smart       |                       | By: | /s/      Cecil B. Pickett |
|                            |                         |                       |   |   |
|                            |                         |                       |   | an      authorized representative of |
|                            |                         |                       |   | Schering-Plough      Research Institute |
|                            |                         |                       |   |   |
| Name:                           | Eric      W. Smart           |                       | Name: | Cecil      B. Pickett, Ph.D. |
|                            |                         |                       |   |   |
| Title:                          | VP      Business Development |                       | Title: | President,      SPRI |
|                            |                         |                       |   |   |
| Date:                           | January      10, 2006        |                       | Date: | January      13,2006 |

----

| - | Commuting expenses to and/or from your place of      business or residence (excluding transportation costs to and/or from the      airport for SPRI-requestedbusiness) |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| - | Add-on costs with respect to outside services,      including but not limited to mark-up for the work product of outside      professionals, including but not limited to    freelancers |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| - | Meals (except during travel periods in connection      with the services rendered to SPRI).  For this exception,      reasonableness shall be measured at US rates of $50 for dinner and $25      each for breakfast and lunch, tax and      tip included in all cases |
|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| - | Administrative and/or overhead percentages |
|---|--------------------------------------------|

| - | Agency presentations for new      business |
|---|--------------------------------------------|

| - | Business-class air travel.  Business-class air travel      is only reimbursable if approved in writing in advance by the area Vice      President |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

| - | First-class air travel |
|---|------------------------|

| - | Mark-up on any out-of-pocket      expenses |
|---|--------------------------------------------|

| - | Traveltime |
|---|------------|

| - | Gifts to SPRI’s      employees |
|---|--------------------------------------|

| - | Entertainment of SPRI’s      employees |
|---|----------------------------------------------|

----